ArticleJournal of translational medicine2025
Plasma exosomal tsRNA may be used as a marker for differential diagnosis of benign and malignant pulmonary nodules.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Combinatorial Model of Serum tsRNAs as a Diagnostic Biomarker for Non-Small Cell Lung Cancer.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundtRNA-derived small RNAs (tsRNAs) have garnered significant attention in the field of cancer research, however, exosomal tsRNAs remain relatively understudied as potential biomarkers in the pulmonary nodules. This study aims to identify exosomal tsRNAs that are differentially expressed between benign and malignant pulmonary nodules, integrate these findings with other clinical parameters, and develop a novel predictive model to estimate the likelihood of malignancy in pulmonary nodules.
methodsExosomes were extracted from plasma of patients with benign pulmonary nodules and malignant pulmonary nodules (early-stage lung cancer), then characterized using transmission electron microscopy (TEM), qNano, and western blot. Differentially expressed tsRNAs were identified through small RNA microarray screening and validated by Quantitative Real-Time PCR (qRT-PCR). Receiver operating characteristic (ROC) analysis evaluated their diagnostic efficiency, while logistic regression integrated blood and imaging data to build a predictive model. Diagnostic performance was further assessed using random forest and nomogram analyses.
resultsA total of 43 differentially expressed tsRNAs were identified through small RNA array analysis. Among these, the expression levels of 3'tiRNA-43-GlyGCC-4 and tRF3-17-GlyTCC were significantly higher in patients with benign pulmonary nodules compared to those with early-stage lung cancer. Conversely, the expression of 5'Leader-ValAAC-1-2 was significantly lower in benign cases than in early-stage lung cancer patients. Using logistic regression, a predictive model was constructed by combining these tsRNA biomarkers with blood-based and imaging parameters. The model demonstrated excellent performance in distinguishing early-stage lung cancer from benign pulmonary nodules, achieving an area under the curve (AUC) of 0.9559, with a sensitivity of 91.06% and a specificity of 91.53%.
conclusionOur model highlights its potential as a robust tool for predicting the malignancy probability of pulmonary nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.